Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-11-07

Clinical Trial Update: Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating mirtazapine for anxiety in children and adolescents with pervasive developmental disorders completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • mirtazapine (mirtazapine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Autism Spectrum Disorders | Phase 3 | Status: COMPLETED | Results posted: 2018-11-07